Introduction

Fabry disease, a panethnic X-linked lysosomal disease, is characterized by accumulation of glycosphingolipids, mainly globotriaosylceramide and its deacylated form globotriaosylsphingosine (Lyso-Gb3), in many types of cells [1,2]. Although enzyme-based screening has been implemented for Fabry disease, it may fail to detect up to one-third of heterozygous females [2]. Recently, genetic screening has been developed for the high-risk population in both male and female patients [3]. A Sequenom iPLEX assay has been designed and validated to identify α-galactosidase A (GLA) gene mutations and variants with 100% accuracy and sensitivity in Taiwan [4].

The aim of the present study was to apply the Sequenom iPLEX assay to screen 26 hotspot mutations and variants of GLA, which are involved in Taiwanese Fabry disease, in a cohort of young stroke patients.

Methods and materials

The Stroke Registry in Chang Gung Healthcare System in Taiwan [5] has established a blood sample bank collecting important DNA. The study protocol was in compliance with the Helsinki Declaration and approved by the institutional review board of Linkou Chang Gung Memorial Hospital.

Young stroke patients were aged 18–55 years and included 488 males and 173 females with ischaemic stroke [17 males and four females with transient ischaemic attack (TIA)] and 272 males and 67 females with hypertensive intracerebral hemorrhage (HICH).

Keywords:
Fabry disease, genetic screening, GLA gene, young stroke
Informed consent for the genetic analysis was obtained from all recruited patients.

Ischaemic stroke subtypes were classified according to our previous study [6]. Hypertension-related HICH was considered when the hematoma was located in the basal ganglion (putamen, thalamus), cerebellum and pons. The definitions of vascular risk factors and clinical survey for young stroke were mentioned in our previous study [6].

The 26 Fabry disease GLA mutations and their protein nomenclature are listed in Table S1. These mutations/variants included 21 GLA mutation single-nucleotide polymorphisms reported in Taiwan [4] and five GLA benign variants previously detected in patients with stroke [4]. The protocol of MassARRAY-based mutation genotyping using the assay Designer v.4.0 software (Agena Bioscience, San Diego, CA, USA) is mentioned after Table S1. A leukocyte GLA activity assay was determined according to the previous method [1]. The diagnosis of Fabry disease was based on a leukocyte GLA activity <4.76 nmol/mg protein/h.

**Table 1** The frequency of Fabry disease in young stroke screening in Asian and non-Asian countries

| Country | Age     | Stroke subtype                  | Number of patients | % mutation in gender | % mutation in stroke subtype |
|---------|---------|---------------------------------|--------------------|----------------------|-----------------------------|
| Asia    | 18-91   | IS (CI + TIA) 2081, HS 339      | 2420 (1902 males + 518 females) | Total 0.62% [12 males (0.63%), and three females (0.58%)] | IS (CI + TIA) 15 (0.72%), HS 0% |
| Non-Asian | 15-70  | IS (CI + TIA) 9431 including cryptogenic IS (CI + TIA) 1586, HS 571, others 403 | 10 405 (6512 males + 3893 females) | Total 0.88% [50 males (0.77%), 42 females (1.08%)] | IS (CI + TIA) 78 (0.83%), cryptogenic IS (CI + TIA) 36 (2.27%), HS 8 (1.40%) |

CI, cerebral infarction; HS, hemorrhagic stroke; IS, ischaemic stroke; TIA, transient ischaemic attack.

**Discussion**

The present study used a Sequenom iPLEX assay as the first-line determination of GLA mutation, further confirmed with plasma GLA enzyme activity assay. The Sequenom iPLEX assay with nation-specific hot-spot mutation genes is suggested as a cost-effective screening method for large series.

In the review of stroke screening (Tables 1 and S3), the overall frequency was 0.62% in 2420 Asian strokes with 0.63% in male subjects, 0.58% in female subjects, 0.72% in 2081 ischaemic strokes and 0% in 339 hemorrhagic strokes. The overall frequency was 0.88% in 10 405 non-Asian strokes with 0.77% in males and 1.08% in females. There were 9431 ischaemic strokes with 1586 cryptogenic strokes, 571 hemorrhagic strokes and 403 others. The frequency of Fabry disease was 0.83% in ischaemic stroke with 2.27% in cryptogenic stroke and 1.40% in hemorrhagic stroke.

The incidence of late-onset IVS4+919G>A mutation is reported as 1:1600 in Taiwanese newborns [7]. Patients carrying IVS4+919G>A and classical Fabry mutations could be distinguished from healthy controls by an elevated plasma lyso-Gb3 [8]. Although similar magnetic resonance imaging findings for both classical Fabry disease and the subtype with IVS4+919G>A mutation [9], patients with IVS4+919G>A have a higher frequency of deep white matter hyperintensities and a higher incidence of infarctions and pulvinar signs than healthy controls [7]. Lyso-Gb3 also correlated with age and left ventricular mass index in Fabry patients with IVS4+919G>A mutation [8].

Our study has two limitations: (i) the Sequenom iPLEX assay cannot cover the full range of Fabry mutations since Fabry disease has more than 800 mutations affecting both males and females; (ii) measurement of lyso-Gb3, a plasmatic biomarker of Fabry disease, was not performed.

**Conclusion**

IVS4+919G>A mutation gene can be seen only in Taiwanese newborn and young ischaemic stroke patients and is rarely detected in other Asian and non-Asian countries. There is less gender difference in
Caucasians, but few Fabry disease occurrences are found in female Asians.

**Acknowledgements**

Grant support from the Research Funding of Chang Gung Memorial Hospital (BMRP274, CMRPG3E2131 and CMRPG3F221) is acknowledged. This research was supported in part by Sanofi Genzyme. The sponsor of the study had no role in the study design, data collection, data analysis, data interpretation or the writing of the report. The corresponding author had full access to all data and had final responsibility for the decision to submit for publication.

**Disclosure of conflict of interest**

T.H.L. and A.P.B. have received honoraria for presentations and board meetings from Sanofi Genzyme; A.P.B. is a member of the European Advisory Board of the Fabry Registry, which is sponsored by Sanofi Genzyme. The other authors declare no conflict of interest.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article:

**Table S1.** α-galactosidase A (GLA) gene mutations and the protein nomenclature.

**Table S2.** Baseline demographics and clinical features of young stroke patients.

**Table S3.** The frequency of Fabry disease in young stroke screening in different countries.

**References**

1. Hwu WL, Chien YH, Lee NC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). *Hum Mutat* 2009; **30**: 1397–1405.

2. Germain DP. Fabry disease. *Orphanet J Rare Dis* 2010; **5**: 30.

3. Poli L, Zedde M, Zini A, et al. Screening for Fabry disease in patients with ischaemic stroke at young age: the Italian Project on Stroke in Young Adults. *Eur J Neurol* 2017; **24**: e12–e14.

4. Lee SH, Li CF, Lin HY, et al. High-throughput detection of common sequence variations of Fabry disease in Taiwan using DNA mass spectrometry. *Mol Genet Metab* 2014; **111**: 507–512.

5. Lee TH, Chang CH, Chang YJ, Chang KC, Chung J. Establishment of electronic chart-based stroke registry system in a medical system in Taiwan. *J Formos Med Assoc* 2011; **110**: 543–547.

6. Lee TH, Hsu WC, Chen CJ, Chen ST. Etiologic study of young ischemic stroke in Taiwan. *Stroke* 2002; **33**: 1950–1955.

7. Lee HJ, Hung SC, Hsu TR, et al. Brain MR imaging findings of cardiac-type Fabry disease with an IVS4+919G>A mutation. *AJNR Am J Neuroradiol* 2016; **37**: 1044–1049.

8. Liao HC, Huang YH, Chen YJ, et al. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A). *Clin Chim Acta* 2013; **426**: 114–120.

9. Lee HJ, Hsu TR, Hung SC, et al. A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation. *BMC Neurol* 2017; **17**: 25.